Login to Your Account



Patent disclosures


Wednesday, February 19, 2014

Biotron Ltd., of Sydney, received a notice of allowance for U.S. Patent application 11/922,281, “Antiviral Compounds and Methods,” for the composition and methods of treatment with its antiviral compound BIT225. BIT225 is in a phase II trial in HCV genotype 3 patients.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription